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Background: To examine the application of continuum models to tuberculosis, HIV, 
and other conditions; to theorize the concept of continua; and to learn lessons that 
could inform the development of improved care and prevention continua as public health 
metrics.
Methods: An analytic review of literature drawn from several fields of health care.
Results: The continuum construct is now part of public health evaluation systems for 
HIV, and is increasingly used in public health and the medical literature. Issues with 
the comparability and optimal design of care continuum models have been raised, and 
their methodologic and theoretic underpinnings and scope of focus have been under- 
addressed. Review of relevant publications suggests that a key limitation of current mod-
els is their lack of measures reflecting incidence and mortality. Issues relating to continua 
data being longitudinal or cross-sectional, definition of numerators and denominators for 
each step, data sources, measures of timeliness of step completion, theoretic models 
to facilitate inferences of causes of care continuum gaps, how measures of prevention 
efforts, reinfection/relapses, and interactions of continua for co-occurring comorbidities 
should be reflected, and how analyses of differences in retention over time, across geo-
graphic regions, and in response to interventions should be conducted are critical to the 
development of sound care and prevention continuum models.
Conclusion: Lessons learned from the application of continuum models to HIV and 
other conditions suggest that the application of well-formulated constructs of care and 
prevention continua, that depict, in well defined, standardized steps, incidence and mor-
tality, along with degrees of and time to screening, engagement in care and prevention, 
treatment and treatment outcomes, including relapse or reinfection, may be vital tools in 
evaluating intervention and program outcomes, and in improving population health and 
population health metrics for a wide range conditions.
Keywords: care continuum, cascade of care, Hiv, hepatitis C, treatment and prevention
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BACKGROUND
The construct of “care continua” has become an important tool 
in the evaluation and improvement of the overall care for certain 
conditions (1–5). Examinations of prevention and care continuum 
constructs have provided valuable insights into the progress of 
individuals and populations through sequential steps of care, and 
into barriers to such progress. While the construct has been in use 
for some time, it has received increased attention and formalized 
acceptance as part of the US’ “HIV care continuum initiative” 
(3) and has now been integrated as part of formal public health 
evaluation systems for HIV. The construct is also now a central 
component of the Joint United Nations Programme on HIV/AIDS 
(UNAIDS), and World Health Organization approaches to HIV 
global public health; the UNAIDS goal of 90% diagnosed, 90% on 
antiretroviral therapy (ART), and 90% virologically suppressed 
(“90–90–90”) implicitly adopts a care-continuum framework 
(6). In fact, the HIV continuum model has been referred to as an 
effective and important tool “for improving the health of people 
living with HIV and for achieving the public health benefits of 
ART” (7) and for “measuring the performance of HIV care and 
treatment programs (8).”
The construct of care continua is also being increasingly used 
in other clinical and public health settings, such as in evaluations 
of care systems for other infections, such as hepatitis C virus 
(HCV), sexually transmitted infections (STIs) (5, 9, 10), and 
non-communicable diseases (e.g., diabetes) (11, 12). However, 
issues with their comparability and optimal design have been 
raised, and their methodologic and theoretic underpinnings 
and their scope of focus have been under-addressed (1, 13, 14). 
Further, despite their increased use, continuum constructs have 
not been formally or consistently applied to a wide range of other 
conditions that might benefit from their use. This includes some 
conditions that may not themselves currently be viewed through 
a continuum of prevention and care lens, but that are frequently 
identified as barriers to progress through the steps of continua 
of other conditions, such as evaluations identifying an adverse 
impact of substance use, misuse, and substance use disorders 
(SUDs) on the HIV or HCV care continua (5, 15, 16).
Our goal is to more fully theorize the continuum construct 
and to help develop understandings, definitions, and applications 
of care continua so as to improve their use as valuable tools for 
scientific, programmatic and public health evaluations and inter-
ventions generally. To achieve this goal, we will examine some 
examples of the valuable application of continuum models and 
explore issues with and limitations of existing models and make 
suggestion for their improved use.
MeTHODS
Examined literature comes from several fields of social science, 
health care and public health over several decades. In order to 
explore the continuum construct through a variety of lenses, 
we adopted an analytic and synthetic approach to draw lessons 
from these diverse sources. This approach relied on traditional 
literature review search methods and on the application of the 
case study methodology and the comparative method (17, 18). 
These methods have been used extensively in social and political 
science (19, 20). They rely on comparisons between and infer-
ences drawn from a modest number of cases (in this analysis; 
“cases” refers to publications or applications of continuum con-
structs) (20). We then sought to review the historic development, 
construction, and application of continuum models, the deline-
ation of specific steps, observations about the clinical and public 
health domains represented and not represented in the models, 
and definitions and data sources.
ReSULTS
early Applications and Basic 
Considerations
The concept of care continua derive from the Piot and Piot-
Fransen models for tuberculosis (TB) and STIs, respectively, 
where models focused on operational considerations that arose 
and that reduced the overall effectiveness of clinical and public 
health efforts already demonstrated by studies to be efficacious 
in idealized settings (4, 21, 22). The Piot-Fransen model has been 
used to understand systems of STI care and the potential impact 
of various interventions by considering, for example, a popula-
tion of women and the proportion (1) with an STD, (2) who are 
symptomatic, (3) seek treatment, (4) go to a health unit, (5) are 
treated correctly, (6) are adherent, (7) are treated effectively, and 
(8) whose partners are treated (21).
Continuum models are usually graphically represented as a 
bar graph where each bar represents the proportion of persons 
completing each step (3, 9, 23–25). In such depictions, if the 
numerator in the first step is then taken to be the denominator 
of the subsequent step (9), each step is essentially represented 
as a separate event and the impact of cumulative losses through 
sequential steps is visually de-emphasized. If, instead, the denom-
inator is kept constant throughout sequential steps, the overall 
impact of cumulative losses is made visually more apparent (25). 
Hayes et al. depicted the progressively decreasing proportions of 
persons completing each step, using visual descriptions of quan-
titative data to assess not only the losses occurring at each step 
but also to allow estimates of the impact of different strategies, 
such as the addition of interventions including active case find-
ing, syndromic treatment, or mass community-level treatment, 
on continuum progress and the impact of such interventions on 
population health (21).
valuable Applications of Continua 
Constructs
HIV likely represents the most established and successful 
application of a continuum model. More recent applications 
of continuum models for the prevention of maternal-to-child 
transmission of HIV and for HIV care generally (26, 27) yielded 
valuable insights and introduced methods for both measuring 
the progress of individuals and populations (2, 3, 15, 23). The 
Centers for Disease Control and Prevention (CDC) formally uses 
two well-defined approaches to evaluate the HIV continuum 
models with the specific intent of both gauging progress toward 
specified public health goals and of directing HIV prevention 
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resources most effectively (3). Both continuum models consist 
of the same five steps but employ different denominators. The 
steps specified in both of these CDC models are the proportions 
diagnosed, linked to care, engaged or retained in care, prescribed 
antiretroviral therapy, and virally suppressed (1, 3, 28). These 
steps correspond to measurable outcomes with clinical and public 
health relevance.
One model, “the prevalence-based HIV care continuum,” 
examines each specified step as a proportion of the total 
number living with HIV including those diagnosed and those 
undiagnosed. The other model, “the diagnosis-based HIV care 
continuum,” uses as a denominator the total number of those diag-
nosed with HIV excluding those who have not been diagnosed. 
The prevalence-based model can be used to assess outcomes for 
broad populations such as young women, but not subgroups of 
these populations, e.g., low-income young women. In contrast, 
the diagnosis-based model allows examination of more detailed 
population subgroups referred to as stratified continuum models.
Similarly, continuum models are also proving valuable in 
identifying gaps and focusing resources for HCV, TB, and other 
services (5, 11, 29). Analyses of the TB continuum led to the obser-
vation that non-adherence to TB treatment was one key obstacle 
to effective completion of TB treatment (30); directly observed 
therapy for TB was developed in response to this observation 
to address treatment adherence, to promote progress through 
the TB continuum and reduce the development of acquired 
resistance, and to reduce ongoing transmission (31, 32). Indeed, 
continua conceptual models for HIV and HCV, and strategies to 
promote engagement and retention, and deter the development 
of acquired drug resistance, have been potently informed by 
global experience with, and continuum-based analyses of, TB 
public health systems and the strategies employed.
Despite the contributions already made through the use of 
continuum models in HIV and other fields, there are a number 
of key issues central to their optimal use as evaluation tools gen-
erally that require further consideration. These include issues of 
theory; the delineation of specific steps standardization; reflect-
ing incidence, time, and disease-specific morbidity and mortality; 
and statistical analysis of the models that will be addressed in the 
sections that follow.
Use of Theoretic Frameworks
An identification of gaps does not in and of itself provide an 
understanding of the reasons for such gaps. An understanding 
of reasons for gaps in or barriers to the progress of individuals or 
populations through the steps of care requires the application of 
an appropriate theoretic framework. Where continuum analyses 
are guided by an appropriate theoretic model, factors affecting 
progress through sequential steps can be more fully examined; for 
example, some studies demonstrate the importance of structural- 
and individual-level factors as determinants of progress through 
continua (16, 33). This is important because the framing as “care” 
continua focuses attention primarily on clinical or biologic end-
points and may, therefore, de-emphasize key explanatory factors 
that fall outside of traditional medical care systems. Eco-social 
theory and the population health approaches of Krieger and 
Rose, respectively, may be valuable underlying theoretic models 
(34, 35). This may facilitate the identification of multi-level fac-
tors impacting individual progress through the continuum, as 
well as examine how progress through continuum steps reflects 
and impacts population-level health (36).
There are frequently large time gaps between demonstrations 
of efficacy and implementation in practice (37). Continua models 
can help focus attention on issues critical to the effectiveness and 
implementation of care and prevention interventions (31). For 
example, there are highly efficacious drugs available to treat TB 
(i.e., they work very well under optimized conditions). However, 
despite this, there are many impediments to TB elimination 
which are predominately “operational,” i.e., the real-world 
effectiveness of these efficacious drugs is reduced by a range of 
multi-level barriers (38, 39). Similarly, there are also now highly 
efficacious drugs for HCV offering the potential for a cure; how-
ever, here, the real world effectiveness of these agents is undercut 
by issues of cost and resultant processes that restrict access 
(40, 41). Continuum models viewed through appropriate multi-
level theory are useful in identifying and guiding efforts that 
address barriers and disparities.
Defining the Steps in a Continuum Model
The steps of any specific continuum model should reflect the 
specific clinical features of that condition and actual processes 
of prevention and care and should be chosen to facilitate elucida-
tion of potential barriers to progress through the continuum so 
that discrete barriers can be addressed. Many continua models 
begin with an initial step of awareness of risk or a condition and 
whether individuals may seek attention or of active testing, case 
finding, or screening of either high-risk or general populations to 
identify those with the condition in question (5, 42). Commonly 
these steps need to be followed by steps of further evaluation and 
engagement and retention in care. The construct “seek, test, treat, 
and retain” is one HIV continuum paradigm that emphasizes this 
common sequence of steps (43). However, in these constructs, the 
category “test” or “screen” may mean a range of things that may 
need to be subdivided into components for optimal monitoring, 
implementation, and improvement. For example, testing can 
refer to HCV antibody testing with or without confirmatory viral 
load testing. Clear characterization of each step can allow specific 
decisions to be made about choice architecture questions, such as 
whether testing is offered as “opt in” or as “opt out” (the use of spe-
cific defaults can significantly improve specific care continuum 
steps) or whether confirmatory testing, where needed, should be 
done as an automatic reflex (44–46).
Reflecting incidence in Continua Models
One key limitation of beginning a continuum model with the 
steps of seeking or testing is that the model then may fail to reflect 
a key public health indicator of disease: incidence. Continuum 
models often begin with the proportion of a general or known-
to-be-positive population who are screened (3, 28). Thus, screen-
ing does not distinguish between prevalent or incident cases. 
Further, models that start with the number of positive cases, 
or those diagnosed as the denominator (as in both CDC HIV 
models), rest entirely on prevalence. Implicit in standard HIV 
continuum models is the notion that increases in the proportion 
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of individuals tested and treated will translate to reductions in 
incidence; however, the failure to distinguish between prevalent 
and incident cases and the failure to reflect measures of incidence 
in the model inappropriately de-emphasizes the importance of 
incidence as a public health indicator, may obscure detection 
and consequences of changes in incidence, and may contribute 
to suboptimal allocation of resources. Distinguishing between 
prevalent and incident cases and to reflect measures of incidence 
in continuum models would improve their value as public health 
tools.
Reflecting Prevention in Continua  
Models
Continua constructs may be valuably applied to prevention 
as well as to care where initial testing or screening are crucial 
both in identifying those affected by the specified condition and 
those who may be at risk for but not yet have the condition (8). 
Most continuum models exclude those testing negative from 
subsequent consideration. Those who test negative for HIV, 
or other specified conditions, may, nonetheless, be at risk and 
consequently require linkage to prevention services, require 
retention in such services, and may require efforts at adherence 
support for risk reduction interventions. In fact, the reliance on a 
step of testing or screening in many continua models, which may 
identify both those already affected and those at risk, highlights 
the importance of understanding continua models as more than a 
linear progression of steps of those affected, but of seeing care and 
prevention as linked and inter-related. As McNairy and El-Sadr 
highlight, the step of testing and screening serve as a critical point 
of intersection between the HIV prevention and care continua 
models (8); however, developing separate prevention and care 
continuum models may miss or obscure the bi-directional rela-
tionships between prevention and care that might be revealed by 
an integrated model. Consequently, one key consideration for 
delineating steps in a continuum model is that of appropriately 
representing factors that relate to primary prevention.
Connections between Diagnosis and 
Treatment in Continua Models
The issue of the connection between screening and acting on the 
results of screening was highlighted by John Sbarbaro in an edito-
rial entitled “To seek, find, and yet fail” written in response to a 
novel TB skin testing program, which identified a high prevalence 
of latently infected persons and yet included no efforts to link 
such persons to evaluations to exclude active TB or initiate treat-
ment of latent TB infection (47). This issue of ensuring effective 
connections between steps of identification and diagnosis, and 
subsequent linkage to and initiation of care, emerge as common 
and critical to care continua for multiple conditions. Approaches 
to reducing gaps after screening include interventions, such as 
patient navigators, or of locating testing and care in community 
settings or in settings where specific risk groups convene (48). 
Significant experience in HIV, HCV, and TB care suggests that 
processes of passive referral to treatment after screening yield 
inferior linkage outcomes compared with systems of active link-
age (10, 49, 50).
Further, diagnostic evaluations are often individualized by 
providers influenced by hidden cognitive processes related to 
the providers’ estimation of a patient’s resources, often within 
constraints imposed by patients, organizations, and insurers 
(51). These organizational constraints (e.g., prior authorizations) 
may themselves pose barriers to medical evaluation completion 
and care continuum progress (40, 52, 53). Similarly, providers, in 
response to guidelines or unconscious biases, differentially apply 
“eligibility criteria” in ways that constituting a “stutter-step” in 
health-care provision, and introducing health disparities (25, 51). 
Further, these evolving factors may lead to variability that poses 
issues for standardized analyses.
Methodologic issues in Continuum Models
Lourenco et  al. have noted that HIV continuum models used 
different countries vary both in enumerated steps and defini-
tions of steps and argue for the need for standardization of the 
HIV continuum construct to allow continuum comparisons 
(14). As discussed in Section “Early Applications and Basic 
Considerations,” the clearly delineated and well-standardized two 
CDC HIV continuum models have proven to be valuable con-
structs. Yet, while these two main models may provide different 
and complementary information, since the numbers of persons 
with HIV who have not been diagnosed can only be estimated not 
directly measured, they may give different estimates for propor-
tions at each of the defined steps (54). Further, both models are 
based on cross-sectional surveillance data and evaluate outcomes 
for the aggregate population studied in a single year and do not 
necessarily reflect individual-level continuum progress. Another 
model being applied in some settings is to examine the continuum 
among those with newly diagnosed HIV (another potentially 
valuable stratification); this model facilitates incorporating con-
siderations of time elapsed between steps, such as the proportion 
achieving viral suppression in the 12 months following diagnosis.
A recent systematic review of publications examining HIV 
continuum models focusing on data sources, methodology, 
and study comparability with respect to these parameters (13). 
Analyses were restricted to published data of HIV care continua 
in well-defined populations, and further restricted to studies 
providing viral suppression data and explicit methods. Despite 
these rigorous inclusion criteria, the authors identified significant 
variability both in the number of steps delineated, and in the data 
source used for steps reported on in the included studies. There 
was also moderate variability in the definitions used to delineate 
both numerators and denominators at each of the steps (e.g., 
different approaches were taken to handling persons who may 
have died, moved away, or been incorrectly notified). A variety 
of time frames or attendance requirements were used in defin-
ing linkage to care, and there was heterogeneity in definitions of 
what contributed to the numerator of those “on ART,” as well as in 
what cut-off constituted virologic suppression. The authors point 
out the potential value of comparisons of continuum analyses 
stratified by geographic regions and time, and among groups, but 
stress the critical importance for consistency in methodology and 
definitions to make such comparisons valid.
Another recent paper examined an 8-step HIV continuum 
model and conducted sensitivity analyses based on variations in 
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continua definitions (55). They found that requiring or not requir-
ing CD4 cell count and viral load testing as part of definitions of 
being linked to care changed proportions of those doing so up to 
18%. Definitions of being on ART (which required at least two 
medication dispensations at least 3 months apart) yielded rates 
20% lower than definitions requiring any ART in that calendar 
year. Overall, they found that the step most sensitive to variations 
in definition was that of the last step, viral suppression. A rigorous 
definition requiring two suppressed viral load determinations at 
least 3 months apart classified 49% as virologically suppressed, 
a proportion 15–25% less than definitions requiring a single 
undetectable viral load.
Overall, these issues highlight the potential impact of varia-
tions in definitions on measured outcomes and the need for defi-
nitional clarity and sensitivity analyses.
Representing Time in Continuum 
Constructs
In current continuum models, the depiction of sequential steps 
along an axis does not represent the time required for transitions 
from one step to the next. For example, the HIV continuum does 
not convey the fact that many people are diagnosed late in the 
course of their infection (52). It also does not convey the timeli-
ness of linkages to care or of achieving viral suppression. Both of 
these are central to the success of treatment as prevention yet they 
are absent from typical HIV continuum constructs. Developing 
models that measure the time between screening, treatment, and 
treatment outcomes would be important.
Another key aspect of prevention and care relates both to the 
defined population and to the recognition that populations are 
not stable overtime (56). For example, continua models are often 
applied to specific geographic regions and individuals may move 
into or out of regions, with consequences both in interruptions in 
their own individual progress through continua and with implica-
tions for how to accurately count such individuals. These consid-
erations may lead to inaccurate assessments of the proportions of 
persons at any given continuum step and require standardization 
to allow appropriate comparisons across geography and over time 
(13). With respect to HIV continua, this issue has been referred 
to as “churn” and has been recognized as leading to inaccurate 
estimates of the number of HIV-infected persons and hence, their 
representation in continua models (54, 57).
Another issue is whether continuum analyses examine 
cross-sectional or longitudinal data, a critical distinction where 
achieving outcomes takes variable amounts of time and where 
outcomes must be sustained overtime. Colasanti et al. examined 
continuous retention in care and continuous viral load sup-
pression over 36 rather than 12- or 24-month periods (1) using 
generalized estimating equations with a logit link and Poisson 
regression log-link tests to evaluation retention in care and the 
prevalence ratio of viral suppression over time, respectively (58). 
Single cross-sectional analyses were found to potentially overes-
timate retention and virologic outcomes, and that longitudinal 
continuum constructs may better describe long-term outcomes 
and reveal disparities potentially obscured by cross-sectional 
annual examinations.
Use of continuum models that reflect longitudinal rather 
than cross-sectional data may be particularly important for 
understanding chronic conditions. For example, if a gonorrhea 
or syphilis case is diagnosed in any given year (where treatment 
can be a single dose or a brief course), treatment and cure should 
be obtained within that same year; a cross-section analysis 
would reflect this. Alternatively, for conditions requiring longer 
treatment (e.g., HIV), cross-sectional analyses may overestimate 
continuum progress.
endpoints for Continua Models: Relapse, 
Reinfection, and Mortality
For both HIV and HCV, a key continuum “endpoint” of viral 
suppression will remain relevant and vital. The rationale for the 
importance of this endpoint is the excellent data that viral load 
suppression translates both into individual-level quality health 
outcomes and population-level conditions that result in lower 
likelihoods of transmission with subsequent reductions in inci-
dence which might then lead to epidemic control, elimination, 
and theoretically eradication (59, 60). Post-viral load suppression 
for HIV or HCV, it will be important to assess rates of relapse 
or reinfection. Similarly, for TB continua models, the common 
endpoint is a mixture of smear and culture conversion and 
completion of a duration of therapy shown in efficacy studies to 
translate to low rates of treatment failure, relapse, and secondary 
transmission. Yet while such valuable biological measures are 
generally depicted as continua endpoints, a critical appraisal of 
care continua suggests the need to reflect reinfection and relapse.
Further, virologic suppression or any other biologic or behav-
ioral outcome measures are at best surrogates of the fundamen-
tally more critical endpoint of mortality. The nineteenth century 
physician and epidemiologist William Farr noted that “the death 
rate is a fact. Everything else is an inference” (61). Issues such 
as whether antiretroviral treatment for HIV infection initiated 
promptly at diagnosis regardless of CD4 count and taken with 
adherence for decades translates to overall improved mortality, 
or whether competing increases in cardiovascular or other forms 
of mortality, associated or not associated with long-term ART 
use, may emerge, are open questions and would be missed by 
continuum analyses that stop at an outcome of viral suppression. 
Therefore, continua models would be more meaningful if the final 
step represented overall mortality or mortality attributable to the 
process being evaluated.
interacting Continua for Multiple 
Conditions
Another issue to be addressed relates to the reality that individuals 
may have more than one health condition, so that an individual 
may in fact be moving through multiple continua which may be 
interrelated to varying degrees. For example, for individuals with 
HIV/HCV, coinfection will be considered as part of both HIV 
and HCV continuum, respectively, and at an individual-level will 
need to move through the steps of both as part of optimal health 
care.
Movement through continuum for two or more conditions 
are likely to be impacted by the specifics of the service delivery 
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systems, which would include whether care occurs through an 
integrated system that addresses all of the conditions or whether 
care is delivered through separate systems. Broadly speaking, this 
relates to the issues of vertical versus horizontal models of care 
and public health funding streams (62, 63). Specifically, it relates 
to a wide variety of models of co-located services such as whether 
HCV care is delivered within an HIV and SUD care setting or if 
individuals are referred elsewhere (64). In fact, use of continuum 
models for single conditions in some sense reproduces and 
reinforces systems of vertical care which have the potential to 
both create barriers themselves and to reframe and de-emphasize 
aspects of care for persons with commonly occurring comorbidi-
ties. To the extent that certain conditions assessed through the use 
of continua are highly overlapping, the use of a disease-specific 
continuum to inform resource allocation may be misleading or 
may miss opportunities for enhanced efficiencies (65).
Movement through one specific continuum may also be 
directly tied to movement through another continuum. Providers 
may make the decision to prioritize achieving HIV viral suppres-
sion prior to the initiation or consideration of HCV treatment; in 
fact, some treatment guidelines and insurance policies suggest or 
“mandate” this (40, 53). In that sense, achieving certain steps of 
HIV prevention and care might appropriately be construed as part 
of a HCV continuum model. Similarly, care systems for HCV may 
require screening for and treatment of SUDs (52). As an example 
of interacting care continua, for persons with HIV-related TB, 
the fact that TB treatment should precede ART initiation, and 
that in analyses the need for TB treatment is associated with late 
ART initiation, demonstrates that progress through these two 
care continua are linked (66). This highlights the need for models 
that clearly delineate the relationships between progress through 
co-occurring care continua.
Understanding that conditions identified as potential barriers 
to progress through a continuum for one condition may in fact 
be disorders requiring intervention, may allow improved under-
standing of the interaction of care systems and of how conditions 
may act as barriers, and may allow the development of more 
refined variables.
Data Sources for and Analyses of 
Continua Constructs
Central to the development of any continuum model is the issue 
of identifying appropriate data sources for each of the identified 
steps. For HIV and TB, such data sources are reasonably well 
developed (67). Current models have relied on combinations of 
information derived from laboratory-based reporting and clinical 
care data, data which are often collected for specific health-care 
systems or regions, which directly inform continua constructs 
that describe these jurisdictions. Their use to populate models 
that combine jurisdictions may lead to inaccurate estimates unless 
careful methods are applied to identify duplicate cases (54). Large 
national databases and electronic medical record systems may be 
useful data sources for continua and further may facilitate the 
examination of interconnections between related models.
In formal analyses, continuum progress could be viewed a 
sequential ordinal variable where earlier stages are prerequisites 
for later stages (e.g., there is no HCV treatment initiation without 
HCV medical evaluation completion). Several formal quantita-
tive analytic methods may be particularly valuable. In formal 
analyses, achieving sequential continuum steps may be viewed 
as a count variable. One approach could be to use the continuous 
ratio model (CRM) which is well suited to sequential outcomes 
of this type (68). With a logit link, exponentiated regression coef-
ficients could indicate how the odds of progressing to a sequential 
continuums stage are affected by an intervention, in terms of an 
odds ratio. The CRM is equivalent to discrete-time survival analy-
sis (69–71) where a continuum step would correspond to time 
periods in survival analysis. Further, for longitudinal continuum 
analyses, generalized estimating equations with a logit link or 
Poisson regression log-link tests, as employed by Colasanti et al. 
may be valuable (1, 58).
In analyzing progress through sequential steps is the con-
sideration of whether each step requires comparable effort or 
results in comparable public health impact. Steps then may need 
to be weighed based on the varying on these considerations. One 
consideration is also whether the steps of a continuum should 
(or do) represent critical individual-level or population-level 
milestones, or whether they primarily reflect measurable mile-
stones, and these may not be the same thing. It might be that 
shifting a continuum curve in which an improvement of some 
proportion at one step may not translate to relevant gains in 
population health, while an improvement of the same propor-
tion at another step might do so (35). This may especially be 
so if the continuum is primarily focused on care and not on 
prevention or other public health metrics, such as incidence, 
timeliness of achieving specified outcomes, or deaths among 
those out of care. Hence, at an individual-level, weights might 
be assigned to steps on the basis of estimates of their relative 
degrees of difficulty, and at a population-level weights might be 
assigned on the basis of estimates of their relative importance to 
population health gains.
This leads to the issue of whether continuum steps are of neces-
sity sequential, or should always be viewed so representationally 
or analytically. Qualitatively, it has been abundantly noted that 
individuals may complete any given step of a continuum model 
and for a range of reasons, not proceed to the next clinically 
logical or desired step, but then at some subsequent point in time 
become re-engaged at the same or even re-enter at an earlier step 
in the continuum model (72). Such stalled or backward move-
ment may be the result of various barriers introduced by both 
providers and patients (e.g., losing health insurance) as part of a 
“stutter-step” (51). In most continuum models, the presumption 
is that those represented in the numerator of one step of necessity 
were in the numerator of the prior step. Yet, Magnal et al. identi-
fied individuals in an HIV continuum analysis who did in fact 
meet definitions for having been prescribed ART or even being 
virologically suppressed but did not meet definitions for having 
been retained in care (24). In their comparison, categorization 
of continuum stages as dependent subsets of prior stages led 
to underestimates of those prescribed ART or achieving viral 
suppression.
An underutilized potential of continuum analyses is their 
application to evaluating the impact of interventions to improve 
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the steps of care. Hayes et al. used graphical representations of 
STI continuum outcomes to estimate the potential impact of dif-
ferent public health strategies on STI outcomes (21). Quantitative 
analyses might consider interventions as either time-invarying 
or time-varying exposures. In quantitative analysis, interventions 
attempting to improve progress through sequential continuum 
steps might in theory be viewed as a time-invarying exposure 
reflecting being on treatment or not. However, because inter-
vention components may vary in content or emphasis through 
each step, interventions addressing multiple steps may be better 
viewed as a time-varying exposure. Similarly, covariates may have 
differential impact on different steps and, therefore, may repre-
sent time-varying confounders, while also potentially being on 
the causal pathway. This suggests that marginal structural models 
may be valuable analytic strategies for evaluating the impact of 
interventions (70, 73).
DiSCUSSiON
implications for improved Use of 
Continuum Models
Review of the literature suggests several key implications for the 
improved use of continua models as clinical and public health 
tools. Models would optimally reflect incidence and distinguish 
incident and prevalent cases. They should reflect disease-specific 
and all-cause morbidity and mortality. Optimal models would 
reflect relapses and reinfections, as well as measures of primary 
and secondary prevention. Models should also reflect the timeli-
ness between steps and have explicit and appropriate definitions, 
data sources, and means for handling those who move or die. 
Models should be understood to require the use of theoretic 
frameworks that consider structural as well as individual causes 
of identified gaps.
Numerous issues in the delivery of care and prevention for 
many conditions resemble those identified in the HIV, HCV, 
and TB continua, including issues of underdiagnoses, gaps in 
linkages between screening and initial diagnosis and engage-
ment in treatment, issues in treatment retention, adherence, 
and relapse, and the interdigitation of continua for relevant 
comorbidities. Systems of care and prevention for many condi-
tions can appropriately and usefully be viewed as consisting of 
a care and prevention continuum including steps of incidence, 
screening/identification, medical/psychosocial evaluation for 
treatment, engagement in evidence-based treatment, retention 
in treatment through to well-defined measures of treatment 
success, as well as degrees of engagement in evidence-based 
interventions to prevent relapse, and measures of overall and 
substance-related-specific mortality. It would be critical to 
define the denominator most relevant to each specified step. 
As with HIV and other continua, the use of various population 
denominators will be important in addressing different ques-
tions. It would be essential to identify appropriate data sources 
for each step, relevant and valid measures of treatment success, 
standardized definitions of numerators and denominators, and 
standard methods to account for those who move or die, and 
handling missing data. It would also be appropriate to reflect 
relationships between a given continuum and continua for key 
comorbidities (57, 74).
Limitations
In reviewing the literature from several fields using traditional 
literature review search methods, some important contributions 
may have been missed and selection bias could have introduced. 
However, the review of literature from multiple fields serves 
as a form of triangulation which may ameliorate this risk 
(75, 76). Some topics meriting discussion may not have been 
optimally covered; decisions were made in an effort to balance 
comprehensiveness and focus. Further, the goals of and specific 
considerations relevant for models intended specifically for ques-
tions unique to either specific health-care systems or to unique 
populations within the substance use field may not have all been 
fully incorporated.
CONCLUSiON
Well-constructed and standardized continua models are prov-
ing to be invaluable for program development, evaluation and 
policy, for public and private health systems in standardizing and 
evaluating outcomes, informing study design, modeling, resource 
allocation, and for facilitating standardized comparisons of an 
expanding range of health outcomes across programs, states, and 
countries. Review of lessons learned from the valuable application 
of continuum constructs suggests that steps of the awareness, of 
screening, of linkage to evidence-based treatment and retention 
in such treatment, and of monitoring timely movement between 
steps, incidence, relapse/reinfection, and mortality. How best to 
reflect some of these factors will require more consideration and 
development. Identifying optimal data sources for continuum 
steps and standardizing definitions for these steps and of rel-
evant numerators and denominators will be needed. Similarly, 
optimizing methods for quantitative analysis of progress through 
continua and of the impact of interventions on such progress is 
also needed.
In conclusion, the application of well-formulated constructs of 
care and prevention continua, that depict, in well defined, stand-
ardized steps, incidence and mortality, along with degrees of and 
time to screening, engagement in care and prevention, treatment, 
and treatment outcomes including relapse or reinfection, may be 
vital tools in evaluating intervention and program outcomes and 
in improving population health and population health metrics for 
a wide range conditions.
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